Schuts Emelie C, Boyd Anders, Muller Anouk E, Mouton Johan W, Prins Jan M
Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Open Forum Infect Dis. 2021 Feb 13;8(4):ofab070. doi: 10.1093/ofid/ofab070. eCollection 2021 Apr.
In hospital settings, restriction of selected classes of antibiotics is usually believed to contribute to containment of resistance development. We performed a systematic review and meta-analysis to assess the effect of restricting the use of specific antibiotic classes on the prevalence of resistant bacterial pathogens.
We conducted a systematic literature search in Embase and PubMed/OVID MEDLINE. We included studies until June 4, 2020 in which a restrictive antibiotic policy was applied and prevalence of resistance and use of antibiotics were reported. We calculated the overall effect of antimicrobial resistance between postintervention versus preintervention periods using pooled odds ratios (ORs) from a mixed-effects model. We stratified meta-analysis by antibiotic-pathogen combinations. We assessed heterogeneity between studies using the I statistic and sources of heterogeneity using meta-regression.
We included 15 individual studies with an overall low quality of evidence. In meta-analysis, significant reductions in resistance were only observed with nonfermenters after restricting fluoroquinolones (OR = 0.77, 95% confidence interval [CI] = 0.62-0.97) and piperacillin-tazobactam (OR = 0.81, 95% CI = 0.72-0.92). High degrees of heterogeneity were observed with studies restricting carbapenem (Enterobacterales, I = 70.8%; nonfermenters, I = 81.9%), third-generation cephalosporins (nonfermenters, I = 63.3%), and fluoroquiolones (nonfermenters, I = 64.0%). Results were comparable when excluding studies with fewer than 50 bacteria. There was no evidence of publication bias for any of the antibiotic-pathogen combinations.
We could not confirm that restricting carbapenems or third-generation cephalosporins leads to decrease in prevalence of antibiotic resistance among Enterobacterales, nonfermenters, or Gram-positive bacteria in hospitalized patients. Nevertheless, reducing fluoroquinolone and piperacilline-tazobactam use may decrease resistance in nonfermenters.
在医院环境中,通常认为限制某些类别的抗生素使用有助于遏制耐药性的发展。我们进行了一项系统评价和荟萃分析,以评估限制特定抗生素类别的使用对耐药细菌病原体流行率的影响。
我们在Embase和PubMed/OVID MEDLINE中进行了系统的文献检索。纳入截至2020年6月4日的研究,这些研究应用了限制性抗生素政策,并报告了耐药率和抗生素使用情况。我们使用混合效应模型的合并比值比(OR)计算干预后与干预前期间抗菌药物耐药性的总体效应。我们按抗生素-病原体组合对荟萃分析进行分层。我们使用I统计量评估研究之间的异质性,并使用meta回归评估异质性来源。
我们纳入了15项个体研究,总体证据质量较低。在荟萃分析中,仅在限制使用氟喹诺酮类药物(OR = 0.77,95%置信区间[CI] = 0.62 - 0.97)和哌拉西林-他唑巴坦(OR = 0.81,95% CI = 0.72 - 0.92)后,非发酵菌的耐药性显著降低。在限制碳青霉烯类药物(肠杆菌科,I = 70.8%;非发酵菌,I = 81.9%)、第三代头孢菌素(非发酵菌,I = 63.3%)和氟喹诺酮类药物(非发酵菌,I = 64.0%)的研究中观察到高度异质性。排除细菌数量少于50的研究后,结果具有可比性。对于任何抗生素-病原体组合,均无发表偏倚的证据。
我们无法证实限制碳青霉烯类药物或第三代头孢菌素的使用会导致住院患者中肠杆菌科、非发酵菌或革兰氏阳性菌的抗生素耐药率降低。然而,减少氟喹诺酮类药物和哌拉西林-他唑巴坦的使用可能会降低非发酵菌的耐药性。